R&D News | pharmaphorum

News

BioSenic slumps as it sidelines bone repair therapy

Belgian biotech BioSenic has suspended a phase 2b trial of ALLOB – a stem cell-derived therapy designed to accelerate bone fracture healing – after it was unable to show e

News

AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

News

Rani’s ‘robotic’ pill delivers injectable osteoporosis drug

US biotech Rani Therapeutics has shown that its oral formulation of a drug for osteoporosis that currently has to be delivered by injection worked as hoped in a first-in-h

News

Biomarker for aggressive fibrotic tumours gets FDA backing

A blood test in development that may be able to predict whether a solid tumour will be particularly aggressive has been given the support of the FDA.

News

Astellas extends protein degrader drive with Cullgen deal

Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders, paying $35 million upfront to partner with US start-up Cul

News